Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021

Rhea-AI Summary

Deciphera Pharmaceuticals (DCPH) will report its Q3 2021 financial results on November 2, 2021, at 4:30 PM ET. Management will hold a conference call to discuss the results and provide corporate updates. Investors can access the call by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) with conference ID 8178994. A webcast will be available on Deciphera's investor relations page.

Deciphera focuses on developing medicines for cancer, leveraging its switch-control kinase inhibitor platform.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, November 2, 2021, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 8178994. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, Hong Kong, Switzerland, Taiwan, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005382/en/

Investor Relations:

Jen Robinson

Deciphera Pharmaceuticals, Inc.

jrobinson@deciphera.com

781-906-1112

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals report its Q3 2021 earnings?

Deciphera Pharmaceuticals will report its Q3 2021 earnings on November 2, 2021.

What time is the conference call for Deciphera's Q3 2021 results?

The conference call will be held at 4:30 PM ET on November 2, 2021.

How can I access the webcast for Deciphera Pharmaceuticals' earnings call?

You can access the webcast on Deciphera's investor relations page after the conference call.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals' stock symbol is DCPH.